IL182693A0 - Methods of preparing indazole compounds - Google Patents

Methods of preparing indazole compounds

Info

Publication number
IL182693A0
IL182693A0 IL182693A IL18269307A IL182693A0 IL 182693 A0 IL182693 A0 IL 182693A0 IL 182693 A IL182693 A IL 182693A IL 18269307 A IL18269307 A IL 18269307A IL 182693 A0 IL182693 A0 IL 182693A0
Authority
IL
Israel
Prior art keywords
methods
indazole compounds
preparing indazole
preparing
compounds
Prior art date
Application number
IL182693A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL182693A0 publication Critical patent/IL182693A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IL182693A 2004-11-02 2007-04-19 Methods of preparing indazole compounds IL182693A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62463504P 2004-11-02 2004-11-02
US71707105P 2005-09-14 2005-09-14
PCT/IB2005/003297 WO2006048744A1 (en) 2004-11-02 2005-10-21 Methods of preparing indazole compounds

Publications (1)

Publication Number Publication Date
IL182693A0 true IL182693A0 (en) 2007-09-20

Family

ID=35744929

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182693A IL182693A0 (en) 2004-11-02 2007-04-19 Methods of preparing indazole compounds

Country Status (14)

Country Link
US (1) US7232910B2 (https=)
EP (1) EP1809621A1 (https=)
JP (1) JP2008518900A (https=)
KR (1) KR20070058690A (https=)
AR (1) AR051754A1 (https=)
AU (1) AU2005300310A1 (https=)
BR (1) BRPI0518203A2 (https=)
CA (1) CA2586174A1 (https=)
IL (1) IL182693A0 (https=)
MX (1) MX2007005291A (https=)
NO (1) NO20071619L (https=)
RU (1) RU2007116107A (https=)
TW (1) TWI294421B (https=)
WO (1) WO2006048744A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ580126A (en) 2007-04-05 2012-03-30 Pfizer Prod Inc Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
WO2010078897A1 (en) * 2009-01-08 2010-07-15 Merck Patent Gmbh Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
CN103826618A (zh) 2011-09-30 2014-05-28 辉瑞大药厂 N-甲基-2-[3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基]苯甲酰胺的药物组合物
US9205078B2 (en) 2011-11-11 2015-12-08 Pfizer Inc. N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
US9899120B2 (en) 2012-11-02 2018-02-20 Nanotek Instruments, Inc. Graphene oxide-coated graphitic foil and processes for producing same
US10087073B2 (en) 2013-02-14 2018-10-02 Nanotek Instruments, Inc. Nano graphene platelet-reinforced composite heat sinks and process for producing same
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
PT3077397T (pt) * 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
PL3102605T3 (pl) 2014-02-04 2019-06-28 Pfizer Inc. Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu
US9617222B1 (en) 2014-03-31 2017-04-11 Senju Pharmaceutical Co., Ltd. Alkynyl indazole derivative and use thereof
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016108106A1 (en) * 2014-12-29 2016-07-07 Shilpa Medicare Limited An improved process for preparation of axitinib
RU2714233C2 (ru) 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent GmbH Pd-l1 antagonist combination treatments
KR20190062515A (ko) 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
WO2020212253A1 (en) 2019-04-18 2020-10-22 Synthon B.V. Process for preparing axitinib, process for purifying the intermediate 2-((3-iodo-1h-indazol-6-yl)thio)-n-methylbenzamide, process for purifying axitinib via the axitinib hcl salt, solid form of the axitinib hcl salt
US20240117030A1 (en) 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7521447B2 (en) * 2003-03-03 2009-04-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
AU2004226586B2 (en) 2003-04-03 2008-12-11 Pfizer Inc. Dosage forms comprising AG013736
WO2006123223A1 (en) 2005-05-19 2006-11-23 Pfizer Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor

Also Published As

Publication number Publication date
RU2007116107A (ru) 2008-11-10
AU2005300310A1 (en) 2006-05-11
WO2006048744A1 (en) 2006-05-11
AR051754A1 (es) 2007-02-07
US7232910B2 (en) 2007-06-19
JP2008518900A (ja) 2008-06-05
NO20071619L (no) 2007-04-25
EP1809621A1 (en) 2007-07-25
US20060094881A1 (en) 2006-05-04
KR20070058690A (ko) 2007-06-08
CA2586174A1 (en) 2006-05-11
MX2007005291A (es) 2007-07-19
TW200621721A (en) 2006-07-01
BRPI0518203A2 (pt) 2009-03-10
TWI294421B (en) 2008-03-11

Similar Documents

Publication Publication Date Title
IL182693A0 (en) Methods of preparing indazole compounds
ZA200702977B (en) Methods of preparing indazole compounds
ZA200702317B (en) Methods for preparing indazole compounds
ZA200704350B (en) Methods for preparing indazole compounds
IL191990A0 (en) Methods of using cd40 binding agents
IL183091A0 (en) Method for preparing n-phenylpyrazole-1-carboxyamides
ZA200805297B (en) Method of using ß-hydroxy-ß-methylbutyrate
GB0823478D0 (en) Method of cementing
IL183176A0 (en) Methods for the preparation of sevoflurane
ZA200704535B (en) Process for preparing rosuvastatin
IL187301A0 (en) Methods of synthesizing 6 - alkylaminoquinoline derivatives
IL185757A0 (en) Methods of decreasing calcifcation
IL182421A0 (en) Process for the preparation of pyrazoles
GB2436262B (en) Process for the preparation of pantoprazole sodium
IL178071A0 (en) Process for preparing pyridazinone compounds
IL177315A0 (en) Process for the preparation of substituted triazole compounds
EP1893625A4 (en) PROCESS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES
ZA200703495B (en) Process for the preparation of irbesartan hydrochloride
IL208214A0 (en) Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
EP1964538A4 (en) PROCESS FOR THE PREPARATION OF PHARMACEUTICAL SUBSTANCES
IL183804A0 (en) Process for preparing substituted 2-alkoxycarbonyl-3-aminothiophenes
EP1917231A4 (en) PROCESS FOR THE PRODUCTION OF BROMOPICRIN
EP2147916A4 (en) PROCESS FOR THE PREPARATION OF SYNTHETIC TAXANES
HUP0401379A3 (en) Process for the preparation of risperidon
PL378094A1 (pl) Sposób wytwarzania aldehydów